Headlands Researchhas announced the acquisition of Clinvest Research, an established site based in Springfield, Missouri. Founded in 1996, Clinvest Research has conducted over 600 trials for chronic diseases and conditions such as headache and migraine, arthritis and chronic pain, and diabetes, as well as weight loss.
By combining Clinvest Research’s expertise with the 11 other sites in the Headlands Research site network studying chronic conditions, Headlands Research is able to access a greater participant population for clinical trials conducted in the US and Canada.
Headlands Research also recently announced the launch of Headlands Research Detroit as well as the acquisition of Headlands Eastern Massachusetts and has plans to continue expanding its network throughout 2023.
Headlands Research Acquires Clinvest Research — the Clinical Research Site Network’s Third Addition of 2023. (2023, May 4). Business Wire.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.